<Like Dewophile, I'm staying in. I don't know about you but I can't find another $125 M company with a late-stage blockbuster in its pipeline that has close to zero efficacy risk. If anyone has any suggestions I'm listening, because I'm sitting on a bunch of cash in my biotech portfolio in addition to my positions in RPRX, JAV, and NVD.[i/]>
Thanks, I'm still holding strongly, too, like you and dewophile. I am curious now about your thoughts on JAV and NVD! :) Are you willing to outline these companies at all on the Biotech Value forum?
Cheers,
Spartex
